Nurix Therapeutics (NRIX) Other Non-Current Liabilities (2019 - 2021)

Nurix Therapeutics (NRIX) has reported Other Non-Current Liabilities for 3 consecutive years, with $796000.0 the latest figure, recorded in Q3 2021.

• In Q3 2021, Other Non-Current Liabilities fell 8.29% year-over-year to $796000.0; the TTM figure through Aug 2021 stood at $796000.0 (down 8.29% YoY), while the FY2020 annual figure was $850000.0, down 51.07% from the prior year.
• Other Non-Current Liabilities retreated to $796000.0 in Q3 2021 per NRIX's latest filing, from $837000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $1.7 million in Q4 2019 and bottomed at $796000.0 in Q3 2021.
• Historically, Other Non-Current Liabilities has averaged $986666.7 across 3 years, with a median of $843500.0 in 2020.
• Annual changes were most pronounced in 2020 — Other Non-Current Liabilities sank 51.07% — and 2021, when it decreased 8.29%.
• Nurix Therapeutics' Other Non-Current Liabilities stood at $1.7 million in 2019, then plunged by 51.07% to $850000.0 in 2020, then decreased by 6.35% to $796000.0 in 2021.
• Business Quant data shows NRIX's Other Non-Current Liabilities at $796000.0 in Q3 2021, $837000.0 in Q2 2021, and $832000.0 in Q1 2021.